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Scales/Balances
The scales (balances) in pharmacies that are used for 
pharmaceutical compounding and/or counting medications 
are very important pieces of equipment in pharmacy prac-
tice. As such, all scales used in Massachusetts pharmacies 
are required to meet stringent requirements for accuracy 
and performance and must be suitable for the intended 
pharmacy application. According to the Commonwealth of 
Massachusetts Division of Standards, scales used in phar-
macies must meet Class II designation and have specific 
values for both readability and sensitivity approved by the 
National Type Evaluation Program (NTEP). All scales must 
have an NTEP Certificate of Conformance (CC) number 
that will be indicated on the scale’s identification plate/
label, and the corresponding certificate must indicate under 
the “Application” heading that the scales may be used for 
a specific purpose (eg, prescription weighing, prescrip-
tion counting, pharmacy use). The National Conference 
on Weights and Measures issues an NTEP CC following 
successful completion of an evaluation of a device, which 
indicates that the device described in the certificate is 
capable of meeting all applicable requirements of NIST 
Handbook 44 and is “legal for trade.”
The Massachusetts Board of Registration in Pharmacy’s 
proposed regulations at 247 Code of Massachusetts 
Regulations (CMR) 9.00, Professional Practice Standards, 
require Board-licensed pharmacies to have a balance 
capable of accurately weighing quantities as small as 10 
mg, which is required to be tested and sealed by the state or 
local sealer of weights and measures at least once during 
each calendar year. For example, if a pharmacy scale 
was sealed in January 2019, the seal remains valid until 
December 31, 2020. The weights and measures official will 
punch the seals for the month and year that the scales were 
tested and sealed. As a note, seals issued in odd years are 
always red and white and those issued in even years are 
always green and white. If a pharmacy has a scale that is 
due for reinspection and the end of the year is nearing, the 
municipality (city or town) should be contacted by phone or 
email 60 to 90 days before the end of the year to request a 
scale inspection to be performed by the appropriate weights 
and measures authorities. Scales that do not meet sensitivity 
and suitability standards or otherwise fail inspection are 
required to be taken out of service immediately and must 
not be used for counting medications or compounding until 
repaired or replaced, then reinspected and placed back 
into service by the weights and measures official. New or 
repaired scales cannot be used until they are duly inspected 
and sealed. Please also note that in accordance with the 
Board’s draft regulations, all new balances purchased by 
the pharmacy shall have the NTEP CC number on the ID 
plate/label to indicate that the device is in fact legal for 
trade. Upon inspection of Board-licensed pharmacies, 
Board inspectors will check to see if a pharmacy’s scale 
has been sealed and is valid for the designated time period.
Finally, with many pharmacies moving from the tradi-
tional mechanical torsion balances to digital versions, it 
is important that these scales be handled carefully and not 
moved around in the pharmacy. Since they are delicate 
instruments and can easily lose their accuracy, it is rec-
ommended that pharmacies using digital scales purchase 
a Class I or Class II certified weight and place it on the 
scale at frequent intervals to verify weighing accuracy. 
Pharmacies should have a policy and procedure in place 
for routine scale calibration, cleaning, and maintenance.
PMP Clinical Platform
The Massachusetts Prescription Monitoring Program 
(PMP) is excited to announce a soon-to-be available new 
clinical platform named the Visano Opioid Stewardship 
platform from Appriss Health. Thanks to funding from the 
Centers for Disease Control and Prevention, Massachusetts 
will be providing a one-year pilot of Visano. This system 
is the next generation substance use disorder (SUD) 
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agency states. “But compounded drugs are not approved 
by the FDA and, therefore, have not been evaluated for 
safety, efficacy or quality. We’ve seen first-hand the harm 
they can cause patients when they’re not appropriately 
compounded.”
HHS, FDA Publish New Action Plan for 
Importation of Certain Prescription Drugs 
The US Department of Health and Human Services 
(HHS) and FDA have published a Safe Importation Ac-
tion Plan to allow for the safe importation of certain drugs 
originally intended for foreign markets. The action plan 
outlines two possible pathways: 
 ♦ Pathway 1 would rely on the authority in the Federal 
Food, Drug, and Cosmetic Act Section 804 to authorize 
demonstration projects to allow importation of drugs 
from Canada. The proposed rules would include con-
ditions to ensure the importation poses no additional 
risk to consumers and must result in a significant cost 
reduction. 
 ♦ Pathway 2 would allow manufacturers to import ver-
sions of FDA-approved drug products that they sell in 
foreign countries that are the same as the US versions. 
Manufacturers would use a new National Drug Code 
for those products, potentially allowing them to of-
fer a lower price than what their current distribution 
contracts require. 
 The action plan states that the final proposal for these 
rules may differ from the descriptions “to reflect further 
consideration of the relevant issues.”
 “Today’s proposal is the result of the hard work by the 
dedicated staff of the FDA, in close collaboration with HHS 
and the White House, to identify potential pathways we can 
pursue to support the safe importation of certain prescription 
drugs,” said Acting FDA Commissioner Ned Sharpless, MD 
in a press release. “We’ve been keenly focused on ensur-
ing the importation approaches we’ve outlined pose no 
additional risk to the public’s health and safety. We know 
there are many operational challenges to address through 
each of these pathways, and are actively working through 
them as we look to formally announce these policies, with 
opportunity for public comment, in the coming months.”
The full action plan can be accessed via the HHS website 
at https://www.hhs.gov/sites/default/files/safe-importation-
action-plan.pdf. 
Pain Reliever Misuse Decreased by 11% 
in 2018, NSDUH Survey Indicates
Prescription drug misuse, including abuse of stimulants 
and pain relievers, decreased in 2018, according to the 
recently released 2018 National Survey on Drug Use and 
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USP Postpones Official Dates of USP 
General Chapters Revisions and Additions
United States Pharmacopeial Convention (USP) has 
announced that the effective date of the following changes 
to USP general chapters will be postponed:
 ♦  General Chapter <795> Pharmaceutical Compound-
ing – Nonsterile Preparations 
 ♦  General Chapter <797> Pharmaceutical Compound-
ing – Sterile Preparations
 ♦  General Chapter <825> Radiopharmaceuticals – Prepa-
ration, Compounding, Dispensing, and Repackaging
The delay is in accordance with USP’s Bylaws, which 
require the official date of the standard to be postponed while 
an appeal is pending. In the meantime, conformance with the 
official versions of Chapters <795> and <797>, including 
the section “Radiopharmaceuticals as CSPs,” will remain 
official, according to a notice posted to the USP website.
Revisions to USP General Chapter <800> Hazardous 
Drugs – Handling in Healthcare Settings are not subject to 
pending appeals, and will become official on December 1, 
2019. During this interim period, Chapter <800> is “infor-
mational and not compendially applicable,” according to the 
USP notice. However, the organization encourages utiliza-
tion of the chapter in the interest of advancing public health. 
USP also notes that it plays no role in enforcement and that 
regulators continue to have the authority to make their own 
determinations regarding enforceability of Chapter <800>. 
FDA Issues Statement on Compounded 
Bulk Drug Substances Ruling
 A US district court judge in Washington, DC, recently 
upheld Food and Drug Administration’s (FDA’s) interpre-
tation of clinical need regarding bulk substances that may 
be used by outsourcing facilities in drug compounding. 
In response to the ruling, FDA has released a statement 
commending the decision as a “victory for public health 
in the first such case since the Drug Quality and Security 
Act (DQSA) was enacted.”
 In March 2019, FDA announced that vasopressin would 
not be included as an approved bulk drug substance because 
there is already an approved product on the market to meet 
the same medical needs. The ruling was in response to a 
challenge of that interpretation. In their statement, the 
agency states that they will continue to evaluate bulk drug 
substances nominated for use in compounding by outsourc-
ing facilities using the same interpretation of clinical need.
 “Our compounding work remains a top priority at the 
agency. We’ve long recognized that compounded drugs can 
serve an important role for patients whose medical needs 
cannot be met by an FDA-approved drug product,” the 
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Health (NSDUH). The annual survey, conducted by the 
Substance Abuse and Mental Health Services Administra-
tion (SAMHSA), a division of HHS, is a primary resource 
for data on mental health and substance use, including abuse 
of prescription drugs, among Americans. 
Key findings of the 2018 NSDUH include: 
 ♦ Past-year abuse of psycotherapeutics decreased from 
6.6 from 6.2%.
 ♦ Past-year abuse of pain relievers decreased from 4.1% 
to 3.6%.
 ♦ Past-year abuse of stimulants decreased from 2.1% 
to 1.9%.
 ♦ Past-year abuse of opioids decreased from 4.2% to 
3.7%.
“This year’s National Survey on Drug Use and Health 
contains very encouraging news: The number of Americans 
misusing pain relievers dropped substantially, and fewer 
young adults are abusing heroin and other substances,” 
said HHS Secretary Alex Azar. “At the same time, many 
challenges remain, with millions of Americans not receiv-
ing treatment they need for substance abuse and mental 
illness. Connecting Americans to evidence-based treatment, 
grounded in the best science we have, is and will remain 
a priority for President Donald Trump, for HHS, and for 
SAMHSA under Assistant Secretary Elinore McCance-
Katz.” 
A recorded presentation of the data, along with a written 
summary and the full report are available on the SAMHSA 
website at https://www.samhsa.gov/data/nsduh/reports-
detailed-tables-2018-NSDUH.
Additional Efforts Needed to Improve 
Naloxone Access, CDC Says 
A new Vital Signs report published by the Centers for 
Disease Control and Prevention (CDC) states that naloxone 
dispensing has grown dramatically since 2012, with rates 
of naloxone prescriptions dispensed more than doubling 
from 2017 to 2018 alone. However, the rate of naloxone 
dispensed per high-dose opioid dispensed remains low, 
with just one naloxone prescription dispensed for every 69 
high-dose opioid prescriptions.
The researchers for the report examined dispensing data 
from IQVIA, a health care, data science, and technology 
company that maintains information on prescriptions from 
50,400 retail pharmacies, representing 92% of all prescrip-
tions in the US. According to their analysis, dispensing rates 
were higher for female recipients than for male recipients, 
and higher for persons aged 60-64 years than for any other 
age group. The researchers also found that the rate of nal-
oxone prescriptions dispensed varied substantially across 
US counties, with rural and micropolitan counties more 
likely to have a low-dispensing rate.
 “Comprehensively addressing the opioid overdose epi-
demic will require efforts to improve naloxone access and 
distribution in tandem with efforts to prevent initiation of 
opioid misuse, improve opioid prescribing, implement harm 
reduction strategies, promote linkage to medications for 
opioid use disorder treatment, and enhance public health 
and public safety partnerships,” the report states in its con-
clusion. “Distribution of naloxone is a critical component of 
the public health response to the opioid overdose epidemic.”
The Vital Signs report can be accessed at www.cdc.gov/
mmwr/volumes/68/wr/mm6831e1.htm. 
Altaire Pharmaceuticals Recalls Multiple 
OTC Ophthalmic Products 
Due to a lack of sterility assurance, Altaire Pharma-
ceuticals, Inc, is voluntarily recalling over-the-counter 
(OTC) drug products and lots sold as generic ophthalmic 
medications at Walgreens, Walmart, CVS, and other retail 
pharmacies. To date, there have been no reports of adverse 
events related to the recalled products. 
A full list of the affected products and lot numbers, as 
well as instructions on how to return the product, are avail-
able through the following press releases: 
 ♦ Altaire Pharmaceuticals, Inc. Issues Voluntary Recall 
Of Multiple Ophthalmic Products Sold At CVS
 ♦ Altaire Pharmaceuticals, Inc. Issues Voluntary Recall 
of Multiple Ophthalmic Products Sold at Wal Mart
 ♦ Altaire Pharmaceuticals, Inc. Issues Voluntary Recall 
of Multiple Ophthalmic Products Sold at Walgreens
 ♦ Altaire Pharmaceuticals, Inc. Issues Voluntary Recall 
of Multiple Ophthalmic Products
Adverse reactions or quality problems experienced with 
the use of this product may be reported to FDA’s MedWatch 
Adverse Event Reporting program.
Pharmacists Invited to Participate in 
NAPLEX Pharmacy Practice Survey
The National Association of Boards of Pharmacy® 
(NABP®) sent email invitations to randomly-selected 
pharmacists in all areas of practice encouraging them to 
participate in the NAPLEX Pharmacy Practice Analysis 
Survey. Analysis of the survey results is used to evaluate 
the North American Pharmacist Licensure Examination® 
(NAPLEX®) competency statements.
The analysis of practice supports the relevance of the 
NAPLEX competency statements, which define the content 
for the examination. This analysis helps ensure that com-
petency statements, otherwise known as the examination 
“blueprint,” are in line with pharmacy practice standards 
and measure the knowledge, skills, and abilities of entry-
level pharmacists. In addition, the review supports the 
NABP mission to protect the public health by providing the 
state boards of pharmacy with a reliable means of assessing 
competency that assists them with licensure decisions to 
support safe and effective practice.
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platform designed to provide a more comprehensive 
approach to addressing SUD and to help prescribers and 
pharmacists make better-informed decisions by providing 
expanded functionality and intelligence within the PMP. 
This platform will aggregate pharmacy prescription data 
and present it in a visually interactive format comprised of 
graphs, additional risk indicators, full prescription details, 
provider resources, and more.
Visano will be available to all those prescribers and 
dispensers registered for the Massachusetts Prescription 
Awareness Tool (MassPAT). It will be accessible via the 
MassPAT web portal or through an integrated system.
A release date has not yet been finalized, but more infor-
mation can be found here and additional resources will be 
available on the MassPAT website in the coming weeks.
Technician Requirements and Duties
Pharmacy technicians (PTs) are individuals who assist 
in filling prescriptions under the direct supervision of a 
pharmacist. They fall into one of three categories: PT 
trainee (PTT), PT, and certified PT. Every technician must 
be properly licensed in accordance with 247 CMR 8.00 
Pharmacy Interns and Technicians, but the requirements 
and scope of practice for each category vary.
Technicians may not administer medications or vaccines, 
perform drug utilization review, conduct clinical conflict 
resolution, contact prescribers concerning therapy clarifi-
cation or therapy modification, provide patient counseling, 
or perform final patient dispensing process validation.
Pharmacy Technician Trainees
 ♦ Must maintain a valid PTT license from the Board.
 ♦ May relay the pharmacist’s offer to counsel.
 ♦ May not take prescriptions over the phone.
 ♦ May assist in the transport of Schedule II controlled 
substances (CS).
 ♦ May not work more than 1,500 hours or more than 
one year, whichever period is shorter, unless: 
◊ the Board grants an extension;
◊ the individual has not yet reached 18 years of 
age; or
◊ the individual has not yet completed at least 500 
hours of employment as a PTT.
Pharmacy Technicians
 ♦ Must maintain a valid PT license from the Board.
 ♦ May relay the pharmacist’s offer to counsel.
 ♦ May accept authorization of refills provided that 
no information has changed from the previous 
prescription.
 ♦ May assist in the transport of Schedule II CS.
Certified Pharmacy Technicians
 ♦ Must maintain a valid PT license from the Board, as 
well as a current certification from a Board-approved 
certifying body, eg, the Pharmacy Technician Certifi-
cation Board’s Certified Pharmacy Technician (CPhT) 
program.
 ♦ May relay the pharmacist’s offer to counsel.
 ♦ After identifying himself or herself as a certified PT, 
may request refill authorizations.
 ♦ May receive new or omitted prescription information.
 ♦ May perform prescription transfers for Schedule VI 
CS.
 ♦ May assist in the transporting and handling of 
Schedule II CS.
 ♦ If certification lapses, the individual is required to 
function as a PT until certification is current.
Did You Know?
 ♦ Our newest Board member, Richard Lopez, MD, was 
welcomed at the September 2019 Board meeting.
 ♦ Retail pharmacies must report drug losses in accor-
dance with Board policy. View the policy here for a 
refresher!
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